Behind the Policy
A forward-looking series delivering clear, strategic insight into the policy and regulatory landscape shaping Canada’s natural health, organic and wellness industry. Translating complex developments into business-relevant intelligence, it connects CHFA’s advocacy work to what matters most—growth, innovation, and market access for members.
Executive Summary
- Health Canada's flagship Red Tape Reduction reform for natural health products (NHPs) is real — but small. It saves the sector an estimated $3 million to $14 million a year.
- Over the same period, other regulatory changes — tighter manufacturing and testing rules, a mandatory relabelling wave, more frequent safety-driven relabels, and new screening paperwork — are adding an estimated $120 million to $170 million a year in new ongoing costs, plus $430 million to $1 billion in one-time costs through 2028.
- The new costs outweigh the savings by at least 8 to 1.
- Almost none of the added cost is tied to a new safety finding. It comes from a tighter interpretation of existing rules, missed sequencing between reforms, and added paperwork.
- CHFA supports strong, proportionate oversight of NHPs. Red tape reduction should be judged by net burden — not by a single reform viewed in isolation.
When Health Canada announced its "Red Tape Reduction" program for Natural Health Products (NHPs), CHFA welcomed it. The goal, we hoped, was to make life simpler (and more cost-effective) for the companies that bring Canadians the vitamins, minerals and probiotics that 80% of us use every day. However, as time has passed since that initial announcement, the question we've been asking is a simple one: reduced compared to what?
That question is important because a red tape reduction program can only be judged one way — by its net effect. Not by whether one process got faster or certain requirements were simplified, but by whether the system, taken as a whole, became easier or harder to operate.
The reform is real. It's also small.
The centrepiece of the red tape reduction program allows the simplest products — those that already match a Health Canada-approved ingredient template (Class I)— to register for sale rather than wait for a full review. That's a genuine improvement.
But it's worth being honest about its size. Class I products were already the fastest and least expensive part of the system: about 50 days and roughly $392 in review costs per product. There wasn't much left to cut. When counted across the products actually filed each year, the savings come to somewhere between $3 million and $14 million annually, depending on which costing method you use.
That's a real number. It is not, on its own, a red tape reduction story.
The part that doesn't make the announcement
While the burden on Class I products got lighter, a series of other regulatory changes has been adding weight elsewhere in the system — changes that didn't come with a press release, but that show up directly in what it costs a Canadian company to keep a product on the shelf:
- Manufacturing and testing requirements have tightened. Updated expectations for good manufacturing practices and how products are made and quality-tested — including more intensive stability testing — now add an estimated $90 to $122 million a year in ongoing costs.
- Every product is moving to a new label format by 2028 — a one-time cost in the hundreds of millions across the sector — and because Health Canada has been making changes to monographs on a continual basis, many companies are relabelling the same product twice or multiple times.
- Safety-driven relabelling has roughly tripled, from about one ingredient review a year to three, each one touching hundreds or thousands of products.
- New screening steps now apply to roughly 20,000 submissions a year, adding paperwork with no safety benefit
Individually, each of these might look like a routine regulatory update. Added together, they don't stay small. On the government's own numbers, the new ongoing costs run industry $120 million to $170 million a year, plus one-time costs of $430 million to $1 billion through 2028, against a saving of, at most, $14 million a year.
This isn't about increased safety
It's imperative to note that almost none of this added cost can be traced back to a new safety concern. The manufacturing standards tightened through interpretation, not new legislation. The double relabelling came from a sequencing gap, not a risk finding. The extra screening is paperwork, not protection. Even the ingredient safety reviews call for warning labels — not removals.
CHFA isn't asking Health Canada to regulate NHPs less. We're asking for the rules to be proportionate to what these products actually are: low-risk, everyday items, made largely by Canadian small businesses that don't have the margins of a pharmaceutical company to absorb costs built for a different risk category.
Why "net burden" is the right way to keep score
A single reform is easy to announce. Net burden is harder to see, because it's spread across dozens of smaller rule changes, interpretations and missed sequencing decisions — the kind of thing that doesn't show up in a headline but shows up every time a company recalculates whether a product is still worth keeping on the market.
That's exactly why CHFA commissioned an independent cost analysis: to put a number on the whole picture, not just the part that was announced. The results are laid out in full in the CHFA Red Tape Brief, prepared by ParadigmForge AI, which maps these costs against Health Canada's own product data and industry-validated figures. Over the coming months, we will unpack what net burden actually means for Canadian companies, both domestically and internationally, for consumers, and for a regulatory system that CHFA wants to see succeed — not shrink.
Read the full analysis
